SAN ANTONIO – A new study co-authored by a UT Health researcher shows how cancer patients with COVID-19 react to different treatments.
According to researchers, the study found new evidence of how cancer patients with COVID-19 react to different treatments, analyzing the treatment of almost 2,200 cancer patients with COVID-19.
The study found that the cancer patients’ mortality rate was 16%, triple the global average.
Dr. Dimpy Shah said patients taking the anti-viral medication Remdesivir had lower mortality rates. However, those taking other drugs engineered to help fight COVID-19 did not.